scispace - formally typeset
S

Sarah E. Jones

Researcher at Imperial College London

Publications -  37
Citations -  2083

Sarah E. Jones is an academic researcher from Imperial College London. The author has contributed to research in topics: Pulmonary rehabilitation & COPD. The author has an hindex of 14, co-authored 37 publications receiving 1651 citations. Previous affiliations of Sarah E. Jones include National Institute for Health Research & Harefield Hospital.

Papers
More filters
Journal ArticleDOI

Minimum clinically important difference for the COPD Assessment Test: a prospective analysis

TL;DR: The most reliable estimate of the minimum important difference of the CAT is 2 points, which could be useful in the clinical interpretation of CAT data, particularly in response to intervention studies.
Journal ArticleDOI

Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation

TL;DR: Sarcopenia affects 15% of patients with stable COPD and impairs function and health status and does not impact on response to PR, which can lead to a reversal of the syndrome in select patients.
Journal ArticleDOI

The five-repetition sit-to-stand test as a functional outcome measure in COPD

TL;DR: The 5STS is reliable, valid and responsive in patients with COPD with an estimated MCID of 1.7 s and is a practical functional outcome measure suitable for use in most healthcare settings.
Journal ArticleDOI

Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study

TL;DR: In this article, the authors determined the prevalence of frailty among patients with stable COPD and examined whether frailty affects completion and outcomes of pulmonary rehabilitation and concluded that patients who are frail respond favourably to rehabilitation and their frailty can be reversed in the short term.
Journal ArticleDOI

The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference

TL;DR: The EQ-5D-5L is a valid and responsive measure of health status in COPD and may provide useful additional cost-effectiveness data in clinical trials.